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The role of thromboxane in cuprophan—induced pulmonary hyperten-
sion. Previous studies demonstrated that acute infusion of cuprophan
activated plasma into experimental animals produce cardiopulmonary
changes which included severe pulmonary hypertension. It was further
suggested that these changes were mediated by complement activation
products. The current study examined the role of arachidomc acid
metabolites in the pathogenesis of cuprophan—induced pulmonary hy-
pertension in the swine. Plasma thromboxane concentrations and
pulmonary arterial pressure rose concomitantly with cuprophan—acti-
vated plasma infusion; both could be inhibited by the specific throm-
boxane synthetase inhibitor, OKY 1581. Likewise, this inhibitor also
blocked the increment in plasma thromboxane concentrations and
pulmonary arterial pressure induced by zymosan—activated plasma. In
vitro incubation of cuprophan—activated plasma with porcine lung
fragments produced significantly higher thromboxane concentrations in
the medium than incubation with other porcine tissues examined. It is
postulated that the complement activation products formed in the
plasma during cuprophan exposure subsequently stimulated release of
thromboxane from the lungs and other tissues upon infusion of the
plasma into animals. The thromboxane, in turn, triggers the pulmonary
hypertension.
Hemodialysis with cellulosic membrane is often associated
with adverse reactions such as dyspnea, chest pain, systemic
hypotension or hypertension [1—3] and pulmonary hypertension
[4, 5]. Experimental models utilizing swine or sheep have been
developed to study the biological effects of these membrane
materials as they may contribute to some of these reactions
[6—8]. It had been demonstrated that acute bolus infusion of
autologous plasma previously exposed to cuprophan membrane
into animals produced significant leukopenia, hypoxemia,
changes in systemic arterial pressure, decrease in cardiac
output and severe pulmonary hypertension [6—8]. Craddock et
al originally suggested that this pulmonary hypertension was
the direct consequence of leukoagglutination in the pulmonary
vasculature [7]. A subsequent study by Walker et al questioned
whether leukocytes were necessary at all to produce this
alteration in pulmonary hemodynamics [9]. Their study showed
that cuprophan—activated blood could still increase pulmonary
arterial pressure in leukopenic animals, and that this increase
could be blocked by indomethacin.
Our recent study also suggested that the leukopenia and most
of the cardiopulmonary changes could be reproduced by infu-
sion of zymosan—activated plasma or purified porcine CSadesArg
[6]. These data suggested that the anaphylatoxins generated
from complement activation upon cuprophan membrane expo-
sure were mediators of these alterations. The present studies
were performed to: (a) further define the role of arachidonic
acid metabolites in the pathogenesis of the cuprophan—induced
pulmonary hypertension; (b) define the interactions between
the arachidonic acid metabolite thromboxane and the comple-
ment activation products; and (c) identify the potential sources
of this thromboxane produced in response to cuprophan—acti-
vated plasma challenge.
Methods
Animals
Normal three—breed cross swine of either sex were em-
ployed. They were of two different sizes. Larger ones weighing
25 to 35 kg were used for experiments with cuprophan—acti-
vated plasma. Smaller ones weighing 10 to 15 kg were used for
experiments with zymosan—activated plasma and in vitro incu-
bation studies. These animals were sedated with intramuscular
ketamine hydrochloride and anesthetized with intravenous so-
dium pentobarbital before blood drawing or acute hemodynam-
ics experiment as previously described [6]. Blood was obtained
from the animals by arteriotomy and collected in two units of
sodium heparin/ml whole blood. The animals were then re-
placed with an equal volume of normal saline and were allowed
to recover from anesthesia prior to the acute experiments on the
following day.
Platelet rich plasma (PRP) and platelet poor plasma (PPP)
PRP was prepared by centrifugation of heparinized blood tt
200 x g for 10 mm. PPP was prepared by centrifugation of
heparinized blood at 2,000 X g for 20 minutes. Platelet counts in
the supernatant were determined. The counts in the PPP were
less than 15 x l03/d. The counts in the PRP were adjusted to a
standardized concentration of 250 x l03/d.
Cuprophan—activated plasma (CAP)
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The preparation of CAP was performed as previously de-
scribed [6]. The blood compartment of a cuprophan hollow fiber
dialyzer (CF- 1511, Travenol Laboratory, Inc., Deerfield, Illi-
nois, USA) was rinsed with one liter of normal saline. The
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dialysate compartment was filled with normal saline and
clamped off. One hundred and fifty ml of platelet poor plasma
was then recirculated through the dialyzer at 100 mI/mm for 45
minutes at 37°C.
Zymosan—activated plasma (ZAP)
Zymosan (Sigma, St. Louis, Missouri, USA) was gently
boiled in normal saline and incubated with platelet poor plasma
(PPP) at a concentration of 2.5 mg/mI of PPP at 37°C for 30
minutes in the presence of 1 mrvi Mg The zymosan particles
were sedimented by centrifugation.
Control plasma
Control plasma was prepared as previously described [6].
Heparinized autologous plasma was incubated at 37°C for 30
minutes without other additives or stimulation.
Isolation of peripheral leukocytes
Porcine polymorphonuclear cells (PMN) and mononuclear
cells (MNC) were isolated from peripheral blood using Ficoll-
paque (Pharmacia Inc., Piscataway, New Jersey, USA). For
MNC isolation, whole blood was diluted 1:1 with phosphate
buffered saline (PBS). Ten ml of the diluted blood was layered
on top of 4 ml of Ficoll-paque, and spun at 450 x g for 40
minutes at room temperature. The MNC layer at the interphase
between the plasma and the Ficoll-paque was removed. The
cells were then washed and spun at 200 x g for seven minutes
three times to remove platelet contamination and resuspended
in Tyrodes buffer.
For PMN isolation, the erythrocytes and leukocytes were
allowed to settle by gravity. The buffy coat was aspirated and
sedimented by centrifugation at 200 X g for seven minutes at
room temperature. The contaminating erythrocytes were re-
moved by repeated lysis with 0.2% NaCI. The leukocytes were
resuspended in Tyrodes buffer, layered over an equal volume of
Ficoll-paque and spun at 400 X g for 35 minutes at room
temperature. The PMN layer below the Ficoll-paque was aspi-
rated and washed.
Viability of the cells was assessed by trypan blue exclusion
and purity assessed by differential counts on Wright stain of the
smear. Both the viability and purity of the cell populations were
>90%. The approximate yield of the MNC and PMN prepara-
tion were 2.0X106/ml and 1 .6XlO6Iml of whole blood, respec-
tively.
Preparation of other tissues
The lungs, heart, pulmonary arteries, ascending aorta, infe-
rior vena cava, kidneys, liver and spleen were removed from
the swine and placed immediately into Tyrodes buffer bubbled
with 95% oxygen and 5% carbon dioxide at 4°C. Pieces of 200
mg of each of these tissues were excised and used for in vitro
incubation as described below.
Acute animal experimental set—up
For acute hemodynamic studies, the animal was sedated with
intramuscular ketamine hydrochloride and intravenous sodium
pentobarbital. It was then intubated via a tracheostomy and
placed on a volume respirator (RV-4, Ensco, Salt Lake City,
Utah, USA). Intravenous normal saline was continuously given
to replace the fluid loss throughout the acute study.
A balloon—wedge pressure catheter (Critikon, Tampa, Flor-
ida, USA) was placed in the pulmonary artery via the right
internal jugular vein. A 4 French and a 6 French catheter was
used for small and large animals, respectively. The femoral
arteries and veins were cannulated with polyethylene catheters
for pressure monitoring and blood sampling. Blood pressure
from the femoral and pulmonary arteries were continuously
recorded on a 6 channel polygraph (R612, Beckman, Fullerton,
California, USA). Blood samples were collected from the
femoral artery at various time intervals for leukocyte counts
and determination of arachidonic acid metabolite concentra-
tions.
Protocol for acute animal studies
After stable baseline hemodynamic readings were obtained,
0.15 ml/kg body wt of control plasma was infused intravenously
as a bolus. Fifteen minutes later 0.15 mllkg body wt of CAP was
infused intravenously as a bolus. Systemic arterial blood sam-
ples were obtained at baseline, 0.5 and 3.0 minutes after the
infusion. Ten minutes after the CAP injection the selective
thromboxane synthetase inhibitor OKY 1581 was then infused
into a peripheral vein continuously at 0.05 mg/kg body wt/min
for 30 minutes. The animal was then rechallenged with 0.15
mllkg body wt of CAP. To test the dose dependent nature of the
responses to OKY1581, 0.6 mllkg body wt of CAP was then
given after the pulmonary artery pressure—baseline had been
reestablished. OKY1581 infusion was continued during the
injection of this larger dose of CAP.
In a separate set of animals, normal saline in the same volume
instead of 0KY1581 was given as control. Again, 0.15 ml/kg
body wt of CAP was given to the animal intravenously. Ten
minutes later, saline was infused over the next 30 minutes. The
same dose of CAP was then repeated.
A separate set of animals was challenged with 0.2 mI/kg body
wt of ZAP intravenously. This challenge was repeated after 0.05
mg/kg body wt/min of OKY 1581 intravenous infusion for 30
minutes.
Protocol for in vitro studies
To study the potential sources of the thromboxane released in
response to infusion of CAP, different porcine tissues were
incubated with CAP in vitro. Fragments of different solid
tissues weighing 200 mg each as described above were incu-
bated with 5 ml of CAP or PPP for 30 minutes in a shaking water
bath. The incubation was maintained at 37°C under 95% oxygen
and 5% carbon dioxide. A sample of the plasma was removed
before and after incubation for thromboxane determination.
Lung tissues were also incubated with 1 x 103M OKYl58l in
additional experiments.
Five ml of CAP were also incubated with peripheral PMNs,
MNCs or platelets. The final concentrations of PMNs, MNCs
and platelets in the incubation were 4.6 x i03 cells/id, 4.7 x l0
cells/pd and 250 x l0 cells/jd, respectively. For positive
controls, PMNs and MNCs were incubated with a mixture of
arachidonic acid (15 /LM final concentration, Sigma) and calcium
ionophore A23 187 (6.1 M final concentration, Sigma). Platelets
were incubated with type I bovine collagen (50 g/ml final
concentration, Sigma).
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Sample handling
Blood samples for leukocyte counts were placed in liquid
disodium ethylenediaminetetraacetate (EDTA, 20 m final con-
centration). Samples of blood or incubation media for
prostaglandin E2 (PGE2) and thromboxane B2(TXB2) concen-
tration determinations were placed immediately in indometh-
acm (0.1 mg/ml final concentration, Sigma) at 4°C. The plasma
was separated as soon as possible and frozen at —70°C until
assay.
Assays
Blood leukocyte counts as well as isolated leukocyte and
platelet counts were performed on a Coulter counter (S-PLUS,
Coulter Electronics, Irvine, California, USA).
Prostaglandin E2 and TXB2 were extracted from the plasma
as follows. Five hundred tl of plasma was acidified with 1 N
hydrochloric acid and applied onto a SEP-PAK C18 cartridge
(Waters Associated, Milford, Massachusetts, USA). Petroleum
ether was passed through the cartridge. The arachidonic acid
cyclooxygenase products were then eluted with ethyl acetate.
The concentrations of PGE2 and TXB2 in the eluate were
determined using commercially—available radioimmunoassay
kits (Seragen, Boston, Massachusetts, USA).
Statistical analysis
Values were reported as mean Differences in values of
variables were evaluated by Student's paired or unpaired t-test
as appropriate. P values <0,05 were considered as statistically
significant.
Results
Animal studies with CAP
Infusion of control plasma did not produce any change in
pulmonary artery pressure as reported in our previous study
[6]. In contrast, acute bolus intravenous infusion of 0.15 mI/kg
body wt of CAP increased the pulmonary artery pressure from
24 4 to 57 13 mm Hg (P < 0.01) within 30 seconds (Fig. 1).
Concomitantly, arterial plasma thromboxane concentration in-
creased from 0.58 0.09 to 1.69 0.38 ng/ml (P < 0.05).
Thereafter, both the pulmonary artery pressure and the throm-
boxane concentration decreased gradually. Peripheral
leukocyte counts, however, did not change significantly. The
pulmonary artery pressure returned to baseline well within 10
minutes. Continuous OKY1581 infusion at 0.05 mg/kg body
wt/min during the next 30 minutes did not change the pulmo-
nary artery pressure. After the infusion of OKY1581, however,
the same dose of CAP failed to increase either the pulmonary
artery pressure or the plasma thromboxane concentration sig-
nificantly. Again, the leukocyte counts remained unchanged.
Baseline plasma PGE2 concentration was 1.38 0.17 ng/ml and
remained unchanged after CAP infusion with (1.41 0.10
ng/ml, P > 0.05) or without (1.41 0.13 ng/ml, P > 0.05)
pretreatment with OKY 1581.
Figure 2 depicts the mean SEM of the pulmonary artery
pressure of seven animals at baseline (Fig. 2A) and 0.5 minutes
after CAP challenge with or without OKY1581 pretreatment
(Fig. 2B,C,D). The pulmonary hypertension induced by 0.15
mllkg of CAP (Fig. 2B) was abolished by the continuous
infusion of 0.05 mg/kg/mm of OKY1581 (Fig. 2C) as described
Time, mm
Fig. 1. Changes in mean pulmonary artery pressure (PAP), systemic
arterial plasma thromboxane B2(TXB2) concentration and systemic
arterial leukocyte (WBC) Counts in swine (N = 7) in response to acute
intravenous bolus infusion of 0.15 mI/kg body wt of cuprophan acti-
vatedplasma (CAP) with (0) and without (•) Continuous infusion of
0.05 mg/kg body wt/min of 0KY1581. Values are presented as mean
*denotes differences with P < 0.05.
above. This small dose of OKY1581 was, however, unable to
inhibit the pulmonary hypertension induced by intravenous
bolus infusion of a larger dose (0.6 mllkg body wt) of CAP (Fig.
2D); the pulmonary artery pressure increased by two-fold to 48
6 mm Hg (P < 0.01). A representative tracing is shown in
Figure 3.
To rule out the possibility that the abolishment of CAP-
induced pulmonary hypertension seen after 0KY1581 infusion
was simply due to refractoriness of the animal response to
repeat CAP challenge, experiments were conducted on a sepa-
rate set of animals using normal saline as control instead of
0KY1581. The data are presented in Table 1. Upon the initial
0.15 ml/kg CAP challenge, mean pulmonary artery pressure
(PAP) increased from 27.0 1.9 to 50.2 2.8 mm Hg (N = 5,
P < 0.01). After saline infusion for 30 minutes, the same CAP
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Fig. 2. Mean pulmonary artery pressure (PAP) at baseline (A); 0.5 mm
after acute intravenous bolus infusion of 0.15 mi/kg body wr of CAP
without (B); or with (C) continuous infusion of 0.05 mg/kg body wt/min
of 0KY1581; 0.5 mm after 0.6 mI/kg body wt of CAP with 0.05 mg/kg
body wt/min of continuous 0KY1581 (D). Values represent mean
in seven animals. * P < 0.01 vs. baseline.
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Fig. 3. Representative tracings of the pulmonary artery pressure (PAP)
in the swine in response to infusion of control plasma, 0.15 mI/kg body
wt of CAP with or without continuous infusion of 0KY1581, and 0.6
mi/kg body wt of CAP with 0KY1581.
challenge again increased the PAP from 27.2 1.6 to 52.4 4.0
mm Hg (N = 5, P < 0.01), demonstrating that there is no
refractoriness of response to repeat CAP infusion after 30
minutes. In contrast, repeat challenge with CAP failed to elicit
pulmonary hypertension after 0KY1581 infusion as indicated in
Figures 1, 2, 3 and Table 1.
Animal studies with ZAP
The effects of zymosan—activated plasma (ZAP) on pulmo-
nary artery pressure and peripheral leukocyte counts are de-
picted in Figure 4. Intravenous bolus challenge with 0.2 mi/kg
body wt of ZAP likewise induced an increase in mean puimo-
nary artery pressure (from 22.4 1.4 to 56.1 4.6 mm Hg, P
<0.001) and systemic arterial TXB2 concentration (from 0.18
0.08 to 0.66 0.16 ng/ml, P < 0.02). However, in contrast to
CAP, ZAP also induced a significant leukopenia (from 16.6
2.9 x i0 cells/mm3 to 8.1 2.4 x io cells/mm3, P < 0.01).
Pretreatment with continuous infusion with OKY1581 abol-
ished the pulmonary hypertension and the increase in throm-
boxane concentration, but not the leukopenia.
In vitro studies with porcine blood cells
To identify the potential sources of the thromboxane released
by CAP infusion, porcine blood cells were incubated with CAP
in vitro. Incubation of CAP with peripheral blood polymorpho-
nuclear cells, mononuclear cells or platelets did not increase the
plasma thromboxane concentration significantly (Table 2). Pos-
itive controls for polymorphs and mononuclear cells were
provided by incubation of these cells with a mixture of arachi-
donic acid and calcium ionophore A23187. The thromboxane
concentration in the media increased from 0.25 0.08 to 1.92
0.25 ng/ml (N = 4; P < 0.01) for polymorphs; the concentration
increased from 0.53 0.11 to 1.24 0.16 ng/ml (N = 6; P <
0.01) for mononuclear cells. Positive controls for platelets were
performed by incubation with collagen, which increased the
thromboxane concentration from 0.18 0.07 to 6.62 1.53
ng/ml (N = 4; P < 0.05).
In vitro studies with other porcine tissues
When lung fragments were incubated with CAP in vitro for 30
minutes, the concentration of TXB2 in the incubation medium
increased from 0.25 0.05 to 3.83 0.45 nglml (P < 0.01) (Fig.
5). The addition of l0- M OKYl58l to the incubation medium
abolished the increment (from 0.24 0.33 to 0.21 0.07 nglml,
P > 0.05, N = 4). This suggests that in the absence of the
synthetase inhibitor, the thromboxane was produced during the
incubation with CAP, but not preformed and simply released by
the lung tissues as a result of trauma.
Interestingly, incubation of lung fragments with platelet poor
plasma in vitro for 30 minutes also resulted in an increment of
plasma thromboxane concentration (0.33 0.15 to 2.09 0.17
ng/ml, N = 4; P = 0.01). This increment is, however, less than
that observed with lung incubated with CAP.
Incubation of CAP with other porcine tissues yield variable
results (Table 3). Incubation with left atrium, inferior vena
cava, liver and spleen increased the plasma concentrations of
thromboxane (N = 4; P < 0.05). These increments were,
however, significantly lower than those induced by incubation
of CAP with lung tissues (N = 4; P <0.02).
Discussion
We and others have previously demonstrated that acute
intravenous infusion of cuprophan—activated plasma (CAP) into
experimental swine or sheep produced various cardiopul-
monary changes including severe pulmonary hypertension
[6—8]. Infusion of purified porcine CSadesArg into swine produced
rather similar results [61, whereas heat inactivation of plasma
prior to cuprophan exposure abolished the alteration in pulmo-
nary physiology in sheep [71. These two latter observations
suggested that the CAP-induced pulmonary hypertension was
mediated by complement activation products C3a, C5a and/or
their des-Arginine derivatives.
(a) (b) (c) (dl
Baseline 0.15 mI/kg Continuous 0KV Continuous 0KV
CAP + 0.15 mI/kg + 0.6 mI/kg
CAP CAP
0.15m1/kg CAP
30 sec
Eli
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Table I. Changes in mean pulmonary artery pressure (PAP) induced by CAP infusion before and after infusion of 0KY1581 or saline
Initial CAP chal
(N = 5)
lenge Repeat CA
after sali
P challenge
ne (N = 5)
Initial CAP(N =chal7) lenge
Repeat CA
after OKY1
P challenge
581 (N = 7)
PAP PAPPAP PAP PAP PAP PAP PAP
(Pre) (Post) (Pre) (Post) (Pre) (Post) (Pre) (Post)
27.0 50.2a 27.2 52.4a 24.0 59.P 23.0 32.2
±1.9 ±2.8 ±1.6 ±4.0 ±1.4 ±5.2 ±4.3 ±4.2
0.15 ml/kg CAP was given in each instance. Ten minutes after the initial CAP challenge, either saline or OKY 1581 was given as continuous
infusion for 30 minutes. The repeat CAP challenge was then given; Pre, before CAP challenge; Post, 30 seconds after CAP challenge.
a These values are not statistically different from each other; they are however significantly higher than their corresponding baseline values (P
<0.01).
Table 2. Changes in plasma thromboxane concentrations following in
vitro incubation of porcine blood cells with cuprophan—activated
plasma (CAP) and controls
CAP
0' 30'
ng/ml
AA ± Ca lonophore
0' 30'
ng/ml
Collagen
0' 30'
ng/ml
PMN 0.24 0.36
±0.03 ±0.10
0.25 l.92a
±0.08 ±0.25
— —
MNC 0.34 0.37
±0.05 ±0.05
0.53 1.24a
±0.11 ±0.16
— —
PRP 0.29 0.29
±0.06 ±0.04
— — 0.18 6.62"
±0.07 ± 1.53
Abbreviations are: PMN, peripheral polymorphonuclear cells; MNC,
mononuclear cells; PRP, platelet rich plasma; AA arachidonic acid; Ca,
calcium.
a P < 0.01 vs. baseline
b p < 0.05 vs. baseline
production of anaphylatoxins in porcine or sheep blood by
cuprophan exposure is only inferential.
The peptides C3a and C5a are termed anaphylatoxins be-
cause of their abilities to contract guinea—pig ileal smooth—
muscles [12], increase vascular permeability of blood vessels
[13] and cause histamine release from mast cells [14]. However,
some of the biological actions of these peptides on end organs
may be indirect. Human C3a had been shown to release
thromboxane from guinea pig peritoneal—macrophages [15].
Both human and porcine C3a cause contraction of isolated
guinea pig lung—strips, which can be blocked by indomethacin
or aspirin [16]. Porcine CSadesArg has been reported to stimulate
3.0 the release of leukotrienes from guinea pig lung fragments and
to contract guinea pig lung strips. This latter effect could be
inhibited by leukotriene inhibitor FPL55712 [17]. Thus the
complement and arachidonic acid systems seem to be closely
related to each other.
Recognizing some of these interactions between the comple-
ment activation products and arachidonic acid metabolites, and
presuming that anaphylatoxins are formed during porcine
plasma exposure to cuprophan, we investigated the roles of the
cyclooxygenase metabolites of arachidonic acid in CAP-
induced pulmonary hypertension in the present study. Indeed,
there was a significant increment in plasma thromboxane con-
centration concomitant to the rise in pulmonary pressure in
response to CAP infusion into the swine. The increase of both
could be blocked by a thromboxane inhibitor 0KY1581. On the
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Fig. 4. Responses of mean pulmonary artery pressure (PAP), systemic
arterial plasma thromboxane B2(TXB2) concentration, and peripheral
leukocyte (WBC) counts to bolus infusion of 0.2 mI/kg body wt of
zymosan activated plasma (ZAP) into experimental swine (N = 7) with
(0) or without (•) continuous infusion of 0.05 mg/kg body wi/mm of
0KY1581. Values are presented as mean ±5EM. < 0.05.
Indeed, it has been well established that complement is
activated during clinical hemodialysis with cuprophan mem-
branes with the resultant formation of anaphylatoxins C3a and
C5a [10, 11]. However, radioimmunoassays for porcine or
sheep anaphylatoxins are currently unavailable. Therefore, the
20
0
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Fig. 5. Changes in plasma concentration of thromboxane B2(TXB2)
when lung tissues were incubated with CAP in vitro. Incubation was
carried out with (0, N = 5) or without (•, N = 5)0KY1581. Values are
represented as mean 0.01 compared to baseline.
Table 3. Changes in plasma thromboxane concentrations following in
vitro incubation of different porcine tissues with cuprophan—activated
plasma (CAP)
P
0'
ng/ml
30'
ng/ml
P
0' vs. 30'
30' vs.
lung 30'
Lung 0.25 0.05 3.83 0.45 <0.01 —
Renal cortex 0.33 0.06 0.38 0.09 NS <0.01
Renal medulla 0.26 0.03 0.93 0.26 NS <0.01
Left atrium 0.25 0.05 0.42 0.06 <0.02 <0.01
Left ventricle 0.28 0.03 0.28 0.07 NS <0.01
Pulmonary artery 0.31 0.03 0.31 0.06 NS <0.01
Aorta 0.31 0.08 0.30 0.04 NS <0.01
Inferior vena cava 0.33 0.07 0.56 0.07 <0.05 <0.01
Liver 0.40 0.09 0.76 0.06 <0.05 <0.01
Spleen 0.38 0.06 1.67 0,36 <0.05 <0.02
other hand, plasma PGE2 did not change
conditions.
under the same
The compound 0KY1581 had been demonstrated to be a
potent and specific thromboxane synthetase—inhibitor [18]. It
effectively blocks the production of thromboxanes associated
with the aggregation of rabbit platelets, and simultaneously
increased prostaglandin E and F generation. This is in contrast
to the nonspecific inhibitory effects of indomethacin on the
cyclooxygenase pathway. The present study strongly suggested
that the thromboxanes were at least partly responsible for the
CAP-induced pulmonary hypertension in the swine. This was in
agreement with the study in which indomethacin blocked the
pulmonary hypertension in the sheep induced by whole blood
previously exposed to cuprophan membranes [9]. Plasma
thromboxane concentrations were not reported in that study.
Despite the pulmonary hypertension, there was no statisti-
cally significant decrease in the peripheral leukocyte count in
response to a small dose (0.15 mI/kg) of CAP infused in the
present study. This was in accordance with the earlier obser-
vations of ours and others that the pulmonary leukosequestra-
tion did not cause the pulmonary hypertension [6, 9]. Instead,
other vasoactive humoral factors such as anaphylatoxins and
thromboxane were responsible. This absence of significant
leukopenia also suggests that the amount of CSjesArg necessary
to induce pulmonary vascular smooth muscle contraction is
lower than that required for leukoagglutination. This is in
accordance with the in vitro observations that the chemotactic
capabilities of C5a and CSadeSArg occur in the nanomolar range
whereas smooth muscle contraction occurs even in sub-
nanomolar concentrations [19, 20].
Zymosan is known to be a very potent alternative pathway
activator of complement [21]. Infusion of zymosan activated
plasma (ZAP) into the animals in the present study was also
associated with increments in pulmonary artery pressure and
plasma thromboxane concentrations, both of which could be
blocked by the thromboxane synthetase inhibitor. This adds
further support to our hypothesis that CAP-induced pulmonary
hypertension is mediated by complement activation products
and the thromboxanes. There was a minor difference between
the results obtained by CAP and ZAP in the present study; the
peripheral leukocyte counts dropped significantly with ZAP but
not with CAP. This may be due to a difference in the amount of
chemotactic anaphylatoxins contained in the injected plasma
generated by exposure to two different types of surfaces. As
noted above, we could not measure porcine anaphylatoxins
directly. However, in our previous study employing recalcified
human serum, the zymosan surface seemed to be a more potent
activator of complement than the cuprophan surface [22].
It should be pointed out that other intermediates may also be
involved in the pathogenesis of cuprophan—induced pulmonary
hypertension. For example, porcine CSadesArg stimulates
leukotriene release from guinea pig lung [17] as mentioned
above and infusion of leukotriene C4 increases the output of
thromboxane A2 from isolated guinea pig lung [231. Thus it is
conceivable that the leukotrienes are intermediates of the
pulmonary hypertensive effects of complement fragments in-
duced by plasma exposure to cuprophan.
We postulate that the abolishment of CAP-induced pulmo-
nary hypertension by 0KY1581 is due to thromboxane synthe-
sis blockade. One may question if it is possible that OKY1S81
shunts the arachidonic acid metabolism to the prostacyclin
synthetase pathway so that the increased production of the
vasodilatory prostacyclin is the mechanism by which 0KY1581
blocks the pulmonary hypertension. This possibility is rather
unlikely since the nonspecific cyclooxygenase inhibitor indo-
methacin also abolishes the pulmonary vasoconstrictive re-
sponse [9].
Besides causing pulmonary hypertension, the thromboxane
generated may also cause other cardiopulmonary alterations
seen with CAP infusion in swine or sheep [6—8]. Intravenous
injection of the thromboxane increased the tracheal insufflation
pressure in guinea pigs [24] and increased airway pressure as
*
3.0
1.0'
Time, mm
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well as pulmonary artery pressure in dogs [251. Intraventricular
administration of thromboxane into dogs also produced a mild
elevation of systemic arterial pressure and mild depression of
myocardial contractility [25]. These effects of thromboxanes
are consistent with the pulmonary and systemic hypertension,
hypoxemia as well as the rise in left ventricular end—diastolic
pressure observed in swine in our earlier studies [6].
The sources of the thromboxane released by CAP in either
the swine or sheep models are unknown. Since the pulmonary
artery pressure rose within seconds after the CAP infusion, we
postulated that the tissues releasing the thromboxanes must be
within the blood or in close contact with the blood. In humans,
platelets are rich in thromboxane [26], although other tissues
such as polymorphonuclear cells [27] thoracic duct lympho-
cytes [28] and the lungs [28, 29] have been demonstrated to
produce these metabolites. Sheep peripheral lymphocytes also
produce thromboxane upon stimulus [301. It should be noted
that species differ in their abilities to release thromboxane by
certain tissues [31]. We first examined the porcine peripheral
blood cells by incubating them in vitro with CAP. None of the
examined blood cell types, including polymorphonuclear and
mononuclear cells as well as platelets, released thromboxane
appreciably. They did, however, respond to the appropriate
positive controls (arachidonic acids + calcium ionophore and
collagen). Therefore, CAP did not seem to be an adequate
stimulus to these hematogenous cells to produce thromboxane.
The solid tissues were next examined. We found that the
lungs produced more thromboxane than any other tissues in
response to CAP in vitro. The thromboxanes were synthesized
by the lungs during and not before the incubation, since the
addition of the thromboxane synthetase inhibitor at the begin-
ning of the incubation period abolished the increments in
plasma thromboxane concentrations. Trauma of the lung tis-
sues during removal from the animals and slicing did not
stimulate thromboxane production.
Interestingly, significant amounts of thromboxane were re-
leased by the lung tissues when incubated with porcine plasma
not previously exposed to cuprophan, although the magnitude
was significantly smaller than that produced by incubation with
CAP. The reason for this release is unknown. Presumably the
porcine lung tissues have a high tendency to synthesize throm-
boxane in response to different stimuli in vitro.
Incubation of CAP with other porcine solid tissues yielded
variable results. Left atrium, inferior vena cava, liver and
spleen seemed to generate thromboxane, but the magnitude was
smaller than that generated by the lungs. The relative contribu-
tions of the thromboxane from these organs in mediating the
CAP-induced pulmonary hypertension in intact animals are yet
to be determined.
In summary, acute intravenous infusion of cuprophan acti-
vated plasma in the swine caused an increase in pulmonary
artery pressure and plasma thromboxane concentration. These
increases could be inhibited by a specific thromboxane synthe-
tase inhibitor. In vitro studies suggest that this thromboxane
was derived from various solid organs, with the lungs being the
most abundant source. Based on the current and previous
studies, we postulated the following sequence of events. Expo-
sure of autologous porcine plasma to the cuprophan dialysis
membranes results in formation of anaphylatoxins C3a, C5a and
their desArg derivatives. When this cuprophan—activated
plasma is infused into experimental swine, C5a or CSadesArg
cause pulmonary leukosequestration and peripheral leukope-
nia. Complement C5a, C3a and/or their desArg derivatives also
stimulate various organs to release thromboxane. These arachi-
donic acid metabolites in turn mediate the pulmonary hyperten-
sion and probably the hypoxemia seen in this model.
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